| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
139,126,000 |
| Market
Cap: |
126.22(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.8537 - $4.83 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile bluebird bio is a company focused on the pursuit of curative gene therapies for severe genetic diseases. Co. has late-stage clinical and research programs for the treatment of sickle cell disease (SCD), ss-thalassemia and cerebral adrenoleukodystrophy and is developing research to apply new technologies to these and other diseases. Using a proprietary lentiviral vector platform, Co. custom designs each of its therapies to address the underlying cause of disease by introducing a functional copy of a gene to patients' own isolated hematopoietic stem cells. Co. is developing lovotibeglogene autotemcel as a one-time treatment for patients with SCD.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
3,834 |
34,841 |
57,218 |
116,663 |
| Total Sell Value |
$3,726 |
$44,583 |
$128,469 |
$435,194 |
| Total People Sold |
1 |
4 |
5 |
9 |
| Total Sell Transactions |
1 |
9 |
12 |
23 |
| End Date |
2024-03-28 |
2023-12-26 |
2023-06-27 |
2022-06-27 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Walsh Jeffrey T. |
Chief Operating Officer |
• – – |
2015-03-10 |
4 |
OE |
$2.09 |
$21,945 |
D/D |
10,500 |
10,500 |
|
- |
|
| Cole Jason |
SVP, Secy. & General Counsel |
• – – |
2015-03-09 |
4 |
AS |
$110.42 |
$1,115,166 |
D/D |
(10,000) |
0 |
|
- |
|
| Cole Jason |
SVP, Secy. & General Counsel |
• – – |
2015-03-09 |
4 |
OE |
$22.53 |
$225,300 |
D/D |
10,000 |
10,000 |
|
- |
|
| Davidson David |
Chief Medical Officer |
• – – |
2015-03-02 |
4 |
AS |
$94.57 |
$379,378 |
D/D |
(4,000) |
0 |
|
- |
|
| Davidson David |
Chief Medical Officer |
• – – |
2015-03-02 |
4 |
OE |
$2.09 |
$8,360 |
D/D |
4,000 |
4,000 |
|
- |
|
| Walsh Jeffrey T. |
Chief Operating Officer |
• – – |
2015-02-10 |
4 |
AS |
$85.18 |
$896,095 |
D/D |
(10,500) |
0 |
|
- |
|
| Walsh Jeffrey T. |
Chief Operating Officer |
• – – |
2015-02-10 |
4 |
OE |
$2.09 |
$21,945 |
D/D |
10,500 |
10,500 |
|
- |
|
| Leschly Nick |
President and CEO |
• • – |
2015-02-03 |
4 |
A |
$0.00 |
$0 |
I/I |
7,373 |
7,504 |
|
- |
|
| Trv Gp, Llc |
10% Owner |
– – • |
2015-02-03 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,515,917) |
0 |
|
- |
|
| Trv Gp, Llc |
10% Owner |
– – • |
2015-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
300,863 |
300,863 |
|
- |
|
| Tepper Robert I |
Director |
– • • |
2015-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
62,479 |
89,017 |
|
- |
|
| Tepper Robert I |
Director |
– • • |
2015-02-03 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,515,917) |
0 |
|
- |
|
| Tepper Robert I |
Director |
– • • |
2015-02-03 |
4 |
A |
$0.00 |
$0 |
I/I |
300,863 |
300,863 |
|
- |
|
| Davidson David |
Chief Medical Officer |
• – – |
2015-02-02 |
4 |
AS |
$94.54 |
$382,501 |
D/D |
(4,000) |
0 |
|
- |
|
| Davidson David |
Chief Medical Officer |
• – – |
2015-02-02 |
4 |
OE |
$2.09 |
$8,346 |
D/D |
4,000 |
4,000 |
|
- |
|
| Gillis Steven |
Director |
– • – |
2015-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
448 |
1,670 |
|
- |
|
| Gillis Steven |
Director |
– • – |
2015-01-30 |
4 |
D |
$0.00 |
$0 |
I/I |
(179,360) |
861,751 |
|
- |
|
| Walsh Jeffrey T. |
Chief Operating Officer |
• – – |
2015-01-12 |
4 |
AS |
$99.53 |
$1,087,454 |
D/D |
(10,500) |
0 |
|
- |
|
| Walsh Jeffrey T. |
Chief Operating Officer |
• – – |
2015-01-12 |
4 |
OE |
$2.09 |
$21,945 |
D/D |
10,500 |
10,500 |
|
- |
|
| Sullivan Eric |
Principal Accounting Officer |
• – – |
2015-01-02 |
4 |
AS |
$88.24 |
$337,531 |
D/D |
(3,750) |
0 |
|
- |
|
| Sullivan Eric |
Principal Accounting Officer |
• – – |
2015-01-02 |
4 |
OE |
$20.70 |
$78,568 |
D/D |
3,750 |
3,750 |
|
- |
|
| Finer Mitchell H. |
Chief Scientific Officer |
• – – |
2015-01-02 |
4 |
AS |
$88.24 |
$2,700,248 |
D/D |
(30,000) |
0 |
|
- |
|
| Finer Mitchell H. |
Chief Scientific Officer |
• – – |
2015-01-02 |
4 |
OE |
$0.95 |
$40,127 |
D/D |
30,000 |
30,000 |
|
- |
|
| Davidson David |
Chief Medical Officer |
• – – |
2015-01-02 |
4 |
AS |
$88.24 |
$360,033 |
D/D |
(4,000) |
0 |
|
- |
|
| Davidson David |
Chief Medical Officer |
• – – |
2015-01-02 |
4 |
OE |
$2.09 |
$8,346 |
D/D |
4,000 |
4,000 |
|
- |
|
940 Records found
|
|
Page 31 of 38 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.04 (4.28%) 
